BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 38069396)

  • 1. Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.
    Zavarykina TM; Lomskova PK; Pronina IV; Khokhlova SV; Stenina MB; Sukhikh GT
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh HE; Kim YS
    Medicine (Baltimore); 2018 Oct; 97(42):e12862. PubMed ID: 30334995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy: unlocking the potentials of cell-free DNA.
    Chu D; Park BH
    Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA in the Management of Early-Stage Breast Cancer.
    Vlataki K; Antonouli S; Kalyvioti C; Lampri E; Kamina S; Mauri D; Harissis HV; Magklara A
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
    Addanki S; Meas S; Sarli VN; Singh B; Lucci A
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer.
    Gianni C; Palleschi M; Merloni F; Di Menna G; Sirico M; Sarti S; Virga A; Ulivi P; Cecconetto L; Mariotti M; De Giorgi U
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
    Zhang X; Ju S; Wang X; Cong H
    Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.
    Pomerantz T; Brooks R
    Curr Treat Options Oncol; 2024 Apr; 25(4):510-522. PubMed ID: 38472567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsy in colorectal cancer: Onward and upward.
    Torresan S; de Scordilli M; Bortolot M; Di Nardo P; Foltran L; Fumagalli A; Guardascione M; Ongaro E; Puglisi F
    Crit Rev Oncol Hematol; 2024 Feb; 194():104242. PubMed ID: 38128627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.
    García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB
    Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients.
    Igari F; Tanaka H; Giuliano AE
    Crit Rev Oncol Hematol; 2022 Jul; 175():103725. PubMed ID: 35618229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating cell-free tumor DNA analysis in pediatric cancers.
    Andersson D; Fagman H; Dalin MG; Ståhlberg A
    Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
    Luo H; Wei W; Ye Z; Zheng J; Xu RH
    Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA for breast cancer: Review of active clinical trials.
    Baksh M; Mahajan B; Dufresne MM; Shoukry MM; Nussbaum S; Abbaszadeh-Kasbi A; Ashary M; Vandenberg J; Gabriel EM
    Cancer Treat Res Commun; 2022; 32():100609. PubMed ID: 35850075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
    Cirillo M; Craig AFM; Borchmann S; Kurtz DM
    Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring.
    Alemzadeh E; Allahqoli L; Dehghan H; Mazidimoradi A; Ghasempour A; Salehiniya H
    Oncol Res; 2023; 31(5):667-675. PubMed ID: 37547763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.